Ribozyme treatment of diseases or conditions related to levels of NF-kappaB

Abstract

Enzymatic RNA molecules which cleave rel A mRNA.

1 . An enzymatic RNA molecule which cleaves rel A mRNA.  
     
     
         2 . An enzymatic RNA molecule of  claim 1 , the binding arms of which contain sequences complementary to the sequences defined in Table II.  
     
     
         3 . The enzymatic RNA molecule of  claim 1 , the binding arms of which contain sequences complementary to the sequences defined in any one of Tables III, and IV-VII  
     
     
         4 . The enzymatic RNA molecule of  claim 1 ,  2 , or  3 , wherein said RNA molecule is in a hammerhead motif.  
     
     
         5 . The enzymatic RNA molecule of  claim 1 ,  2 , or  3 , wherein said RNA molecule is in a hairpin, hepatitis delta virus, group 1 intron, VS RNA or RNAseP RNA motif.  
     
     
         6 . The enzymatic RNA molecule of  claim 6 , wherein said ribozyme comprises between 12 and 100 bases complementary to said mRNA.  
     
     
         7 . The enzymatic RNA molecule of  claim 6 , wherein said ribozyme comprises between 14 and 24 bases complementary to said mRNA.  
     
     
         8 . Enzymatic RNA molecule consisting essentially of any sequence selected from the group of those shown in Tables IV, V, VI, and VII.  
     
     
         9 . A mammalian cell including an enzymatic RNA molecule of  claim 1 ,  2 , or  3 .  
     
     
         10 . The cell of  claim 8 , wherein said cell is a human cell.  
     
     
         11 . An expression vector including nucleic acid encoding an enzymatic RNA molecule or multiple enzymatic molecules of  claim 1 ,  2 , or  3  in a manner which allows expression of that enzymatic RNA molecule(s) within a mammalian cell.  
     
     
         12 . A mammalian cell including an expression vector of  claim 11 .  
     
     
         13 . The cell of  claim 13 , wherein said cell is a human cell.  
     
     
         14 . A method for treatment of a condition related to the level of NF-κB activity by administering to a patient an enzymatic nucleic acid molecule of  claim 1 ,  2 , or  3 ,  
     
     
         15 . A method for treatment of a condition related to the level of NF-κB activity by administering to a patient an expression vector of  claim 11 .  
     
     
         16 . The method of  claim 14  or  15 , wherein said patient is a human.  
     
     
         17 . The method of  claim 14  wherein said condition is selected from the group consisting of restenosis, rheumatoid arthritis, asthma, inflammatory or autoimmune disorders, and transplant rejection.  
     
     
         18 . The method of  claim 15  wherein said condition is selected from the group consisting of restenosis, rheumatoid arthritis, asthma, inflammatory or autoimmune disorders, and transplant rejection.